{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:10:14Z","timestamp":1791267014473,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Firstly, in a human\n                      <jats:italic>in vitro<\/jats:italic>\n                      model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72 h. After treatment, production of DAMPs and 12 cytokines were analyzed in the supernatant through colorimetric and enzymatic assays. C57\/Bl6 mice were treated with CTLA-4 or PD-1 blocking agents (15 mg\/kg) for 10 days. Before (T0), after three days (T3) and after treatments (T10), ejection fraction, fractional shortening, radial and longitudinal strain were calculated by using bidimensional echocardiography (Vevo 2100, Fujfilm). Fibrosis, necrosis, hypertrophy and vascular NF-kB expression were analyzed through Immunohistochemistry. Myocardial expression of DAMPs (S100- Calgranulin, Fibronectin and Galectine-3), MyD88, NLRP3 and twelve cytokines have been analyzed. Systemic levels of SDF-1, IL-1\u03b2, and IL-6 were analyzed before, during and after ICIs therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Radial and longitudinal strain were decreased after 10 days of ICIs therapy. Histological analysis of NF-kB expression shows that short-term anti-CTLA-4 or anti-PD-1 treatment increased vascular and myocardial inflammation. No myocardial hypertrophy was seen with the exception of the pembrolizumab group. Myocardial fibrosis and expression of galectin-3, pro-collagen 1-\u03b1 and MMP-9 were increased after treatment with all ICIs. Both anti-CTLA-4 or anti-PD-1 treatments increased the expression of DAMPs, NLRP3 inflammasome and MyD88 and induced both\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      the secretion of IL-1\u03b2, TNF-\u03b1 and IL-6. Systemic levels of SDF-1, IL-1\u03b2 and IL-6 were increased during and after treatment with ICIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short therapy with PD-1 and CTLA-4 blocking agents increases vascular expression of NF-kB, systemic SDF-1, IL-1\u03b2, IL-6 levels and myocardial NLRP3, MyD88 and DAMPs expression in preclinical models. A pro-inflammatory cytokine storm was induced in myocardial tissues and in cultured cardiac cells after ICIs therapy. The overall picture of the study suggests new putative biomarkers of ICIs-mediated systemic and myocardial damages potentially useful in clinical cardioncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2022.930797","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T04:28:53Z","timestamp":1662611333000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways"],"prefix":"10.3389","volume":"9","author":[{"given":"Vincenzo","family":"Quagliariello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Passariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabella","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Cipullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Buccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Bisceglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Inno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CMR.0000000000000800","article-title":"Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis","volume":"32","author":"Yin","year":"2022","journal-title":"Melanoma Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jaccao.2020.08.001","article-title":"Inflammatory biomarkers to detect immune checkpoint inhibitor-associated cardiotoxicity in lung cancer patients: ready for prime time?","volume":"2","author":"Aras","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/jcdd9070203","article-title":"ICIs-Related cardiotoxicity in different types of cancer","volume":"9","author":"Dong","year":"2022","journal-title":"J Cardiovasc Dev Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3390\/ijerph19052826","article-title":"Myocardial work brings new insights into left ventricular remodelling in cardio-oncology patients","volume":"19","author":"Vaz Ferreira","year":"2022","journal-title":"Int J Environ Res Public Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e003804","DOI":"10.1161\/CIRCHEARTFAILURE.116.003804","article-title":"Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker","volume":"10","author":"Besler","year":"2017","journal-title":"Circ Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/jpm10040179","article-title":"Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models","volume":"10","author":"Quagliariello","year":"2020","journal-title":"J Pers Med."},{"key":"B16","volume-title":"Australian Public Assessment Report for IPILIMUMAB","year":"2011"},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"H811","DOI":"10.1152\/ajpheart.00385.2009","article-title":"Speckle tracking echocardiography in the assessment of mouse models of cardiac dysfunction","volume":"297","author":"Peng","year":"2009","journal-title":"Am J Physiol Circ Physiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3390\/cancers13122858","article-title":"Immunomodulatory mAbs as tools to investigate on Cis-Interaction of PD-1\/PD-L1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments","volume":"13","author":"Vetrei","year":"2021","journal-title":"Cancers."},{"key":"B20","first-page":"279","article-title":"Strain analysis in the assessment of a mouse model of cardiotoxicity due to chemotherapy: sample for preclinical research","volume":"30","author":"Rea","year":"2016","journal-title":"In Vivo."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/OTT.S157294","article-title":"Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine","volume":"11","author":"De Lorenzo","year":"2018","journal-title":"Onco Targets Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2019.05.028","article-title":"Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab","volume":"292","author":"Quagliariello","year":"2019","journal-title":"Int J Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/ijms23073466","article-title":"Novel bi-specific immuno-modulatory tribodies potentiate T cell activation and increase anti-tumor efficacy","volume":"23","author":"Passariello","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0161779","DOI":"10.1371\/journal.pone.0161779","article-title":"Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology","volume":"11","author":"Selby","year":"2016","journal-title":"PLoS ONE."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e201611","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3389\/fonc.2020.01193","article-title":"Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic?","volume":"10","author":"Sehgal","year":"2020","journal-title":"Front Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fphys.2018.00038","article-title":"Ranolazine attenuates Trastuzumab-induced heart dysfunction by modulating ROS production","volume":"9","author":"Riccio","year":"2018","journal-title":"Front Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/cvr\/cvs298","article-title":"Importance of endothelial NF-\u03baB signalling in vascular remodelling and aortic aneurysm formation","volume":"97","author":"Saito","year":"2013","journal-title":"Cardiovasc Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1161\/ATVBAHA.114.303579","article-title":"Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk","volume":"34","author":"Subramanian","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat Rev Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with cancer immunotherapies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"key":"B36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers14040955","article-title":"Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review","volume":"14","author":"llouchery","year":"2022","journal-title":"Cancers."},{"key":"B37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/FJC.0000000000001026","article-title":"Takotsubo cardiomyopathy as epiphenomenon of cardiotoxicity in patients with cancer: a meta-summary of case reports","volume":"78","author":"Carbone","year":"2021","journal-title":"J Cardiovasc Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005","article-title":"Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: endomyocardial biopsy provides pathological insights to dual diseases","volume":"3","author":"Serzan","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"749834","DOI":"10.3389\/fonc.2021.749834","article-title":"Immune checkpoint inhibitor induced pericarditis and encephalitis in a patient treated with Ipilimumab and Nivolumab for metastatic melanoma: a case report and review of the literature","volume":"11","author":"Braden","year":"2021","journal-title":"Front Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40959-021-00106-x","article-title":"A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors","volume":"7","author":"Lal","year":"2021","journal-title":"Cardiooncology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9874109","DOI":"10.1155\/2018\/9874109","article-title":"The role of toll-like receptor signaling in the progression of heart failure","volume":"2018","author":"Yu","year":"2018","journal-title":"Mediators Inflamm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/eci.12118","article-title":"Targeting inflammatory pathways in myocardial infarction","volume":"43","author":"Christia","year":"2013","journal-title":"Eur J Clin Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/cancers14051145","article-title":"Immune checkpoint inhibitors-associated cardiotoxicity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers."},{"key":"B48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur J Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology Primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/brain\/awz119","article-title":"Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies","volume":"142","author":"Giannoccaro","year":"2019","journal-title":"Brain."},{"key":"B51","doi-asserted-by":"publisher","first-page":"14680","DOI":"10.1038\/ncomms14680","article-title":"T cell costimulation blockade blunts pressure overload-induced heart failure","volume":"8","author":"Kallikourdis","year":"2017","journal-title":"Nat Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"6797","DOI":"10.26355\/eurrev_202111_27124","article-title":"Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19","volume":"25","author":"Quagliariello","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 inflammasome inhibitor, OLT1177 (Dapansutrile), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J Cardiovasc Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.3390\/ijms21207802","article-title":"NLRP3 as putative marker of Ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells","volume":"21","author":"Quagliariello","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B57","first-page":"5151","article-title":"Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury","volume":"12","author":"Miao","year":"2020","journal-title":"Am J Transl Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.yjmcc.2021.08.001","article-title":"MyD88: at the heart of inflammatory signaling and cardiovascular disease","volume":"161","author":"Bayer","year":"2021","journal-title":"J Mol Cell Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol."}],"updated-by":[{"DOI":"10.3389\/fcvm.2023.1129873","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000}}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.930797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T10:28:11Z","timestamp":1674037691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.930797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":59,"alternative-id":["10.3389\/fcvm.2022.930797"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.930797","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"930797"}}